Abstract | BACKGROUND: METHODS: We conducted an observational pilot study in 72 CAD patients with aspirin ± dipyrone comedication in the department of cardiology of the University Hospital Düsseldorf. The primary end point was a composite of death, myocardial infarction (MI) or stroke. The secondary end points were the components of the primary end point. The median follow-up period was 3.2years. RESULTS: The primary end point occurred 67% of patients in the aspirin+dipyrone group as compared to 31% in the aspirin-alone group (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.7 to 12.3; P=0.0028;). All-cause mortality was significantly higher in the aspirin+dipyrone group (44%) than the aspirin-alone group (22%; OR 2.8, 95% CI 1.01 to 7.8; P=0.049). Ischemic events (MI and stroke) were more frequent in the aspirin+dipyrone group as compared to the aspirin alone group as well (OR 4, 95% CI 1.1 to 14; P=0.03). CONCLUSION: In this hypothesis generating pilot analysis, dipyrone medication in aspirin treated coronary artery disease patients is associated with an increased cumulative incidence of death, MI or stroke as well as all-cause mortality and ischemic events. These data have to be confirmed in larger registries and trials. CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov/ct2/show/NCT01402804; Identifier: NCT01402804; Date of registration: July 25, 2011.
|
Authors | Alina Achilles, Annemarie Mohring, Lisa Dannenberg, Kerstin Piayda, Bodo Levkau, Thomas Hohlfeld, Tobias Zeus, Malte Kelm, Amin Polzin |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 236
Pg. 76-81
(Jun 01 2017)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 28262342
(Publication Type: Journal Article, Observational Study)
|
Copyright | Copyright © 2017 Elsevier B.V. All rights reserved. |
Chemical References |
- Analgesics, Non-Narcotic
- Platelet Aggregation Inhibitors
- Dipyrone
- Aspirin
|
Topics |
- Aged
- Aged, 80 and over
- Analgesics, Non-Narcotic
(administration & dosage, adverse effects)
- Aspirin
(administration & dosage)
- Chest Pain
(drug therapy, etiology)
- Coronary Artery Disease
(diagnosis, mortality, physiopathology, therapy)
- Dipyrone
(administration & dosage, adverse effects)
- Drug Interactions
- Female
- Germany
(epidemiology)
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Pilot Projects
- Platelet Aggregation Inhibitors
(administration & dosage)
- Risk Assessment
- Stroke
(epidemiology)
- Treatment Outcome
|